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Abstract
 
Human, but not murine, adenosine deaminase (ADA) forms a complex with the cell mem-
brane protein CD26/dipeptidyl peptidase IV. CD26-bound ADA has been postulated to regu-
late extracellular adenosine levels and to modulate the costimulatory function of CD26 on T
lymphocytes. Absence of ADA–CD26 binding has been implicated in causing severe combined
immunodeficiency due to ADA deficiency. Using human–mouse ADA hybrids and ADA
point mutants, we have localized the amino acids critical for CD26 binding to the helical seg-
ment 126–143. Arg142 in human ADA and Gln142 in mouse ADA largely determine the ca-
pacity to bind CD26. Recombinant human ADA bearing the R142Q mutation had normal
catalytic activity per molecule, but markedly impaired binding to a CD26
 
1
 
 ADA-deficient hu-
man T cell line. Reduced CD26 binding was also found with ADA from red cells and T cells
of a healthy individual whose only expressed ADA has the R142Q mutation. Conversely,
ADA with the E217K active site mutation, the only ADA expressed by a severely immunode-
ficient patient, showed normal CD26 binding. These findings argue that ADA binding to
CD26 is not essential for immune function in humans.
Key words: adenosine deaminase deﬁciency • severe combined immunodeﬁciency • 
T lymphocyte • protein–protein interaction • adenosine deaminase complexing protein
 
Introduction
 
Adenosine deaminase (ADA)
 
1
 
 deficiency in humans causes
profound lymphopenia, which is evident by midgestation
and results in SCID during infancy (1, 2). Various effects
 
of adenosine (Ado) and 2
 
9
 
-deoxyadenosine (dAdo) have
been implicated in pathogenesis (3). Skeletal, neurologic,
and hepatic abnormalities that occur in some patients may
also be due to the metabolic disorder, but these are of less
clinical relevance than the immunodeficiency. In contrast
to the phenotype in humans, ADA knockout mice have
normal lymphoid development at birth and die perinatally
of hepatic and pulmonary injury (4, 5). Lymphopenia de-
velops postnatally in strains genetically engineered to ex-
press only placental ADA, but these animals die at a few
weeks of age from lung injury (4–6). The greater lym-
phoid selectivity in humans than mice may reflect differ-
ences in purine metabolism, tissue sensitivity to ADA sub-
strates, or timing of development. In this context it is
intriguing that human ADA, but not murine ADA, can
form a complex with a multifunctional membrane protein
that has a role in regulating thymocyte proliferation and T
cell activation.
The ADA of human erythrocytes behaves as a soluble
monomer of 
 
z
 
41 kD. Larger forms (
 
.
 
200 kD) found in
extracts of other tissues of humans, rabbits, and cattle are
due to the binding of ADA to a homodimeric membrane
glycoprotein with subunit 
 
M
 
r
 
 
 
z 
 
110 kD (7–9). This so-
called “ADA complexing protein” (ADA-CP) was shown
 
to bind two ADA monomers with 
 
K
 
A
 
 of 4–20 nM (8, 10).
ADA-CP occurs on secretory or absorptive surfaces of epi-
thelia of liver, gut, kidney, and exocrine glands (11). Mice
lack “large” forms of ADA (12), but were found to possess
a membrane protein with the tissue distribution and size of
ADA-CP, which cross-reacted with Ab to human ADA-
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9
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raphy. 
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CP, but bound neither murine nor human ADA (13). Un-
like human and bovine ADA, murine ADA did not bind to
rabbit ADA-CP (10).
ADA-CP has been identified as a protein known both as
CD26 and dipeptidyl peptidase IV (DPPIV; 14, 15). CD26
was first defined as an antigen on activated human T lym-
phocytes (16), and DPPIV as a widely distributed ectoen-
zyme that cleaves peptides with Pro or Ala at position 2,
including several hormones, neuropeptides, and cytokines
(17, 18). CD26 and DPPIV cDNAs from human T cells
and intestine predict the same 766-residue, 88-kD poly-
peptide (19, 20). This type II membrane protein has 6
NH
 
2
 
-terminal cytoplasmic residues, a 34-residue mem-
brane anchor, a large extracellular domain consisting of a
glycosylated “stalk”, a cysteine-rich segment (residues 290–
552), and a COOH-terminal region that bears the serine
protease (DPPIV) active site (residues 628–632 [21]). Resi-
dues 294 and 340–343 of the cysteine-rich segment are es-
sential for binding ADA (22, 23). In addition to ADA,
CD26 has been reported to bind collagen, fibronectin, the
CD45 tyrosine phosphatase, and the HIV-1 Tat protein
(for reviews, see references 21 and 24).
Among lymphoid cells, CD26 is expressed on medullary
thymocytes, blood T cells with a helper/memory pheno-
type, activated B cells, and NK cells. On T cells, CD26 acts
as a “co-stimulator” of antigen receptor–mediated activa-
tion (24). CD26 ligation also stimulates the proliferation of
thymocytes and other hematopoietic cells in the mouse and
rat (25, 26). It has been variously proposed that in humans,
binding of ADA is important to the costimulatory function
of CD26, that such binding protects lymphocytes from ef-
fects of extracellular Ado, and that immunodeficiency in
patients with ADA deficiency is due to the absence of
CD26-associated ADA (15, 23, 24, 27). We have defined
the amino acid residues of human ADA that are essential
for CD26 binding, and investigated the effects on CD26
binding of ADA mutations from individuals with ADA de-
ficiency. Our findings are not consistent with some predic-
tions about the nature of the CD26 binding site; neither do
they support the hypothesis that ADA–CD26 binding is es-
sential for immune function in humans.
 
Materials and Methods
 
Materials
 
DEAE-Sepharose fast flow, Superose 12, and CNBr-activated
Sepharose 4B were obtained from Amersham Pharmacia Biotech.
ADA-Sepharose was prepared by coupling calf mucosal ADA
(Sigma-Aldrich and Boehringer) to CNBr-activated Sepharose
4B according to the manufacturer’s instructions. Plasmid pZC11
and 
 
Escherichia coli
 
 SØ3834 were provided by Dr. Rod Kellems
(University of Texas, Houston, TX). Goat anti–human ADA an-
tiserum was provided by Dr. Dan Wiginton (University of Cin-
cinnati, Cincinnati, OH). The mouse mAb 1C5 was prepared
against ADA purified from human T cell leukemia cells (Hersh-
field, M.S., unpublished details).
 
Lymphoid Cells and Cell Lines
 
Activated T lymphocytes were prepared by culturing blood
mononuclear cells with phytohemagglutinin and IL-2 as de-
scribed (28), except that the cells were grown in AIM-V serum-
free medium (Life Technologies). The HTLV-1–transformed
AlNe cell line derived from an ADA-deficient patient (provided
by Dr. Ken Weinberg, Los Angeles Children’s Hospital, Los An-
geles, CA) was also maintained in AIM-V medium.
 
Enzyme Assays
 
DPPIV activity was determined using Gly-Pro-
 
p
 
-nitroanilide
tosylate (Sigma-Aldrich) as substrate, monitoring A405 at 37
 
8
 
C
(29). ADA activity was determined by monitoring the decrease in
A263 at 37
 
8
 
C using as substrate 150 
 
m
 
M Ado in 50 mM Tris-
HCl, pH 7.4. Both the CD26 and ADA assays were performed in
96-well microtiter plates (Costar UV plate; Corning Inc.) in reac-
tion volumes of 0.2 ml, using a SpectraMax plus spectrophotom-
eter (Molecular Devices). ADA was also assayed by a radiochem-
ical-TLC method (28). Protein was determined using the
bicinchoninic acid (BCA) method (Pierce Chemical Co.) with
BSA as standard.
 
Rabbit Kidney CD26/DPPIV
 
CD26/DPPIV was purified from New Zealand white rabbit
kidney homogenates by a published procedure involving DEAE-
Sepharose and ADA-Sepharose 4B chromatography (30). In
some preparations, the ADA-Sepharose column was eluted with
6 M urea in 0.01 M KPO
 
4
 
, pH 7.4, 0.1% Triton X-100, as de-
scribed (31). Fractions with DPPIV activity were pooled, dia-
lyzed against 0.01 M KPO
 
4
 
, pH 7.4, 0.1% Triton X-100, and
stored at 
 
2
 
20
 
8
 
C. The purified preparation had a DPPIV-specific
activity of 7,883 
 
m
 
mol min
 
2
 
1
 
mg
 
2
 
1
 
. A partially purified prepara-
tion used for screening ADA–CD26 binding had DPPIV activity
of 6.5–7.2 
 
m
 
mol min
 
2
 
1
 
mg
 
2
 
1
 
. ADA activity of these preparations
was 
 
,
 
0.003 
 
m
 
mol min
 
2
 
1
 
mg
 
2
 
1
 
.
 
Bovine ADA cDNA
 
Standard methods were used to amplify, clone, and sequence
cDNA (32, 33). Degenerate reverse transcription PCR primers
were used to clone the ADA coding region from bovine thymus
RNA: (
 
1
 
)5
 
9
 
ATCGAAGCTTCCATGGCCCAGACRCCCGC-
MTTC, (
 
2
 
)5
 
9
 
GGCCATGGAGAGGTAGCCACGACACCTT-
CACAGACA. Both strands were sequenced by the dideoxy
method (sequence data are available from EMBL/GenBank/DDBJ
under accession no. AF280603). The expressed product of the bo-
vine ADA cDNA was enzymatically active (Kelly, S.J., and M.S.
Hershfield, unpublished data).
 
Construction of Human–Mouse ADA cDNA Hybrids and Point 
Mutants, and Expression of ADA for CD26 Binding Studies
 
cDNAs consisting of segments from both the human (34) and
mouse (35) ADA coding regions were made by overlap extension
PCR (36; Tables I and II). The P126Q, R142Q, R149Q,
A215T, and E217K ADA mutants have been identified in human
subjects (37–40); their expression in 
 
E
 
.
 
 coli
 
 strain SØ3834 has
been reported (41). Other mutations (see Results) were intro-
duced into the wild-type human or mouse ADA cDNAs by
PCR mutagenesis essentially as described (37, 41). All final ADA
cDNA PCR products were cloned into pBluescript II KS or
pBluescript SK and fully sequenced using the ABI 377 PRISM
DNA Sequencing Instrument (Applied Biosystems). 
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ADA cDNAs were ligated into the NcoI site of pZ (derived
from pZC11 from which wild-type human ADA cDNA had
been excised [42]). pZ/ADA plasmids were used to transform 
 
E
 
.
 
coli
 
 SØ3834, which has a deletion of the bacterial ADA gene (42).
Single transformant colonies were grown at 37
 
8
 
C in Luria broth/
carb/tet medium to constitutively express ADA, as described
(41). Under these conditions, the yield of wild-type mouse ADA
was four- to sixfold higher than for human ADA, determined
both by activity assay (Table III) and by Western blotting with
cross-reacting goat anti–human ADA antiserum (not shown).
Studies with human–mouse ADA hybrids (Table III) and results
not presented indicate that this difference in expression is related
to the presence in human ADA of NH
 
2
 
-terminal codons used in-
frequently in 
 
E
 
.
 
 coli
 
.
To prepare ADA for CD26 binding studies, the cells from 100-
ml overnight cultures were sonicated in 3 ml of lysis buffer (41).
 
In some experiments the cells from 1-liter cultures were disrupted
in 20 ml of lysis buffer using a Microfluidizer Model M-110L
(Microfluidics, Inc.). After centrifugation (20,190 
 
g
 
, 15 min, 4
 
8
 
C),
supernatants were passed through 0.2 
 
m
 
m filters and dialyzed at
4
 
8
 
C against 0.01 M KPO
 
4
 
, pH 7.4. In addition to assaying ADA
activity, aliquots of these lysates (20-
 
m
 
g protein) were analyzed by
Western blotting using goat anti–human ADA antiserum, as de-
scribed (41). Western blotting was also performed with the 1C5
mouse mAb to human ADA (1:2,000 dilution of ammonium sul-
fate–concentrated mouse ascites); a goat anti–mouse IgG–horse-
radish peroxidase conjugate (Santa Cruz Biotechnology, Inc.) was
used as a second Ab, and was detected with the Enhanced
Chemiluminescence System (Amersham Pharmacia Biotech).
 
ADA-CD26 Binding
 
FPLC Screening.
 
In the standard assay, dialyzed (0.01 M
KPO
 
4
 
, pH 7.4) lysates of pZ/ADA cDNA-transformed 
 
E
 
.
 
 coli
 
SØ3834 cells containing 100–250 nmol/min of ADA activity (di-
luted as necessary with dialyzed lysate of untransformed SØ3834
cells) were combined with 10–30 nmol/min (DPPIV activity) of
rabbit CD26 in 0.01 M KPO
 
4
 
, pH 7.4, 0.1% Triton X-100, total
volume 150 
 
m
 
l. After incubating for 2 h at 37
 
8
 
C, the entire mix-
ture was injected onto a 1.5 
 
3
 
 30 cm Superose 12 column equili-
brated with 50 mM Tris-HCl, pH 8.4 (fast protein liquid chro-
matography [FPLC] system; Amersham Pharmacia Biotech). The
column was eluted with this buffer at room temperature, flow rate
0.5 ml/min. Fractions (0.5 ml) were assayed for ADA and DPPIV
activities, and the percentage of total ADA activity associated with
the peak of DPPIV activity (CD26) was calculated. In some ex-
periments the column was equilibrated and eluted with 50 mM
Tris-HCl, pH 8.4, containing 150 mM NaCl. This shifted the
peak of free (41 kD) ADA activity from fraction 25 to fraction 27,
but neither the DPPIV activity peak nor the amount of ADA ac-
tivity associated with the DPPIV peak were altered.
 
Gel Mobility Shift Assay.
 
[
 
35
 
S]Met-labeled ADA was gener-
ated in vitro from ADA cDNA constructs in pBluescript, using
the TNT Coupled Wheat Germ Extract System (Promega) ac-
cording to the manufacturer’s instructions (this system was used
in preference to rabbit reticulocyte extracts because it possessed
very low endogenous ADA-like activity). Translation products
were analyzed by SDS-PAGE and fluorography, and were also
electrophoresed on cellulose acetate and stained for ADA activity
in situ, as described (28). Aliquots of the translation mixtures
containing equal amounts of 
 
35
 
S-labeled products were then in-
cubated (2 h, 37
 
8
 
C) with 0.7–2.2 nmol/min of rabbit CD26/DP-
PIV in 0.01 M KPO
 
4
 
, pH 7.4, 0.1% Triton X-100, total volume
20 
 
m
 
l. These reaction mixtures were then electrophoresed on a
3–15% gradient nondenaturing PAGE gel (pH 8.8, 30% acryl-
amide, 0.8% bisacrylamide; running conditions 60 V/cm, 18 h,
4
 
8
 
C [43]). [
 
35
 
S]ADA was located by fluorography.
 
Recombinant ADA Binding to AlNe T Cells
 
Aliquots (25 
 
m
 
l) of pZ/ADA cDNA-transformed SØ3834 ly-
sates containing 400 nmol/min of ADA activity were added to 2 
 
3
 
10
 
7 
 
AlNe T cells in 1 ml of serum-free growth medium and in-
cubated 2 h at 37
 
8
 
C. The T cells were then washed three times
with PBS, pH 7.4, and lysed by freezing and thawing (or by soni-
cation, which gave identical results) in 150 
 
m
 
l of 25 mM Tris-
HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 0.1% Triton X-100.
After centrifugation, the supernatant was analyzed as described
above for the FPLC CD26 binding assay. ADA binding to intact
AlNe cells was determined by flow cytometry using the 1C5 anti-
ADA mAb (see below). For these studies, 10
 
6
 
 AlNe cells were in-
 
Table I.
 
Human–Mouse ADA Hybrids
 
Construct
 
*
 
Templates
(ADA cDNAs)
 
‡
 
Primers
 
‡
 
M1–81/H82–363 I: M wild-type 1, 2
II: H wild-type 3, 4
III: Products of I and II 1, 4
H1–81/M 82–125/H126–363 I: H 1–81/ M 82–352 5, 6
II: H wild-type 7, 4
III: Products of I and II 5, 4
H1–125/M126–143/H144–363 I: H wild-type  5, 8
II: H wild-type 9, 4
III: Products of I and II 5, 4
H1–143/M144–247/H248–363 I: H wild-type 5, 10
II: M 1–247/H 248–363 11, 4
III: Products of I and II 5, 4
H1–247/M248–352 I: H wild-type 5, 12
II: M wild-type 13, 14
III: Products of I and II 5, 14
H1–81/M82–352 I: H wild-type 5, 15
II: M wild-type 16, 14
III: Products of I and II 5, 14
M1–247/ 248–363 I: M wild-type 1, 17
II: H wild-type 18, 4
III: Products of I and II 1, 4
M1–125/H126–143/M144–352 I: M wild-type 1, 6
II: M wild-type 11, 14
III: Products of I and II 1, 14
 
*
 
H, human ADA; M, mouse ADA. Numbers indicate amino acid resi-
dues.
 
‡
 
PCR reactions I and II generated DNA fragments with 45–84-bp
central overlaps. These were gel purified, combined, annealed, and am-
plified in PCR reaction III to yield the desired hybrid constructs (col-
umn 1). ADA cDNA templates and the primer pairs for reactions I, II,
and III are listed in columns 2 and 3 (primer sequences are in Table II).
In addition to the templates and primers (10 pmol each), each 50 µl
PCR reaction contained 4 dNTPs (0.2 mM each), 1
 
3
 
 PCR buffer, 1.5
mM MgCl
 
2
 
, and 2.5 U of AmpliTaq DNA polymerase (PerkinElmer).
Thermal cycling was optimized for each reaction. 
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cubated for 60 min at 37
 
8
 
C in 1 ml of medium containing aliquots
of untransformed or ADA-expressing SØ3834 lysates. The cells
were then washed with cold PBS containing 1% BSA and 0.1%
sodium azide (PBSW) and processed for flow cytometry.
 
Flow Cytometry
 
Surface antigens and bound ADA on AlNe T cells were de-
tected with the following reagents: unconjugated anti-ADA mAb
1C5 and control mAb P3; and fluorochrome-conjugated Ta1-
RD1 (CD26), B1-RD1 (CD20), T11-RD1 (CD2), mouse
IgG1-RD1, and either fluorescein- or PE-conjugated goat anti–
mouse IgG1 provided by Beckman Coulter (Fullerton, CA). All
Ab incubations were performed in PBSW at 4
 
8
 
C. After washing
with PBSW, cells were fixed with 0.4% paraformaldehyde, and
analyzed using an Epics Elite XL flow cytometer (Beckman
Coulter). Data were processed using the FACSConvert™ and
CellQuest™ software programs (Becton Dickinson).
 
Results
 
Binding of Recombinant ADAs to Rabbit CD26.
 
Like the
enzymes isolated from tissues (10), human and mouse ADA
expressed in 
 
E
 
.
 
 coli
 
 SØ3834 differ markedly in ability to
 
Table II.
 
PCR Primers Used in Constructing Human–Mouse ADA Hybrids
 
Primer sequence
 
*
 
Location in ADA cDNA
 
‡
 
1
 
(
 
1
 
)CGCGCGAATTCGGGCACCATGGCCCAGACACCCGCATTC  M1–21 (EcoRI/NcoI)
2 (2)CATCTCTACAAACTCATAGGCGATCCTCTTGATGGCCTCTCTGCA Reverse of primer 3
3 (1)TGCAGAGAGGCCATCAAGAGGATCGCCTATGAGTTTGTAGAGATG  M223–243/H244–267
4 (2)GCGCAAGCTTCGGGCCATGGTCTTCAGAGGTTCTGCCCTGCAG H1073–1092 (HindIII/NcoI)
5 (1)CGCGCGAATTCGGGCACCATGGCCCAGACGCCCGCCTTCGAC  H1–24 (EcoRI/NcoI)
6 (2)GTCTCGCTCCCCCTCCTGCAGGCCCTGGCCCACTAGGGCTACCACCT Reverse of primer 7
CGTCTGGGGTGACGTCCCCTTCAGTCTGGTTCCAGGG
7 (1)CCCTGGAACCAGACTGAAGGGGACGTCACCCCAGACGAGGTGGTAGC M346–375/H376–429
CCTAGTGGGCCAGGGCCTGCAGGAGGGGGAGCGAGAC
8 (2)TGCTTGCTCTCCCTCCTGCAGGCCCTGGTTCACAAGATCCACAACGT H346–375/M376–429
CATCAGGGGTGAGGTCCCCTTCAGCCTGGTTCCAGGG
9 (1)CCTGATGACGTTGTGGATCTTGTGAACCAGGGCCTGCAGGAGGGAGA M376–429/H430–459
GCAAGCATTCGGGGTCAAGGCTCGGTCCATCCTGTGC
10 (2)GCACAGAATGGACCGGACCTTGATGCCAAAGTCTCGCTCCCCCTCCT Reverse of primer 11
GCAGGCCCTGGCCCACTAGGGCTACCACCTCGTCTGG
11 (1)CCAGACGAGGTGGTAGCCCTAGTGGGCCAGGGCCTGCAGGAGGGGGA H376–429/M430–459
GCGAGACTTTGGCATCAAGGTCCGGTCCATTCTGTGC
12 (2)TTCTTTCAGTAGTCTGTTGTAGAGGGCCTGGTCTTCCAGGGTGTG Reverse of primer 13
13 (1)CACACCCTGGAAGACCAGGCCCTCTACAACAGACTACTGAAAGAA H721–741/M742–765
14 (2)GCGCGATATCCGGGCCATGGTCTCTATTGGTATTCTCTGTAGAGCC M1037–1059 (EcoRV/NcoI)
15 (2)CATCTCCACAAACTCGTAGGCGATCCTTTTGATAGCCTCCCGGCA  Reverse of primer 16
16 (1)TGCCGGGAGGCTATCAAAAGGATCGCCTACGAGTTTGTGGAGATG H223–243/M 244–267
17 (2)TTCCTGCCGCAGCCTGTTATAAAGAGCTTCATCCTCGATGGTGTG Reverse of primer 18
18 (1)CACACCATCGAGGATGAAGCTCTTTATAACAGGCTGCGGCAGGAA M721–741/H742–765
*Cloning sites are underlined. The bold italic nucleotides are silent polymorphisms found in human ADA cDNA.
‡The numbers indicate nucleotide position in human (H) or mouse (M) ADA cDNA (adenine of the initiation codon51).
Table III. ADA Activity of Human–Mouse Hybrids Expressed in 
E. coli SØ3834
ADA cDNA
ADA activity
(mean 6 SD)
Wild-type
human ADA
mmol/min per mg protein %
Human wt 3.3 6 0.7 100.0
Mouse wt 12.4 6 1.3 375.7
M1–81/H82–363 13.5 6 2.2 409.0
H1–81/M82–125/H126–363 4.3 6 0.4 130.3
H1–125/M126–143/H144–363
(“m126–143”) 1.2 6 0.1 36.3
H1–143/M144–247/H248–363 2.9 6 0.3 87.8
H1–247/M248–352 2.0 6 0.2 60.6
H1–81/M82–352 1.8 6 0.7 54.5
M1–247/H248–363 12.3 6 3.8 372.7
M1–125/H126–143/M144–352 
(“h126–143”) 13.1 6 3.6 396.9
wt, wild-type; H, human; M, mouse.1227 Richard et al.
bind rabbit kidney CD26/DPPIV. When equal amounts of
ADA activity were compared, z50% of human and ,1%
of mouse ADA activity coeluted with DPPIV activity from
a Superose 12 FPLC column (Fig. 1, A and B). The differ-
ence in CD26 binding could also be demonstrated using
nondenaturing PAGE to assess the effect of rabbit CD26 on
the migration of 35S-labeled human and mouse ADA in
vitro translation products (Fig. 1 C). Addition of unlabeled
human ADA expressed in E. coli SØ3834 (100 nmol/min)
blocked the CD26-induced shift in migration of the human
[35S]ADA translation product, whereas the same amount of
recombinant mouse ADA had no effect (not shown).
Based on these results, we constructed human–mouse
ADA cDNA hybrids (Tables I–III) and used the above as-
says to locate residues necessary for CD26 binding (analo-
gous to human–rat CD26 “swap mutants” used to identify
CD26 residues necessary for ADA binding [22]). To refine
our search, we also used point mutants found in ADA-defi-
cient individuals, which we have previously expressed in
SØ3834 (41). ADA mutants with sufficient catalytic activ-
ity were screened by FPLC, although in some cases using
less ADA activity than in the “standard” assay (see Materials
and Methods). The PAGE assay was used for ADA mutants
with very low catalytic activity. Some mutants could not
be tested because their activity was too low for the FPLC
assay, and their in vitro translation products did not enter
the nondenaturing gel (results not shown).
Initial hybrid screening placed the CD26 binding site be-
tween residues 82 and 248 (Fig. 2, A and B). This interval
was narrowed by results with the R142Q point mutant,
which expressed 28% of wild-type human ADA activity in
SØ3834 (41): in four standard FPLC binding experiments,
10.4 6 2.9% (mean 6 SD) of R142Q ADA activity co-
eluted with DPPIV activity (Fig. 2 C), resulting in 0.9 6 0.5
ADA units bound per unit DPPIV. By comparison, in five
standard experiments with wild-type human ADA, 48.7 6
5.1% of ADA activity coeluted with DPPIV activity, re-
sulting in the binding of 5.9 6 1.4 units of ADA per unit
of DPPIV (Fig. 2, A and B). We also tested the P126Q,
R149Q, and A215T mutants, which expressed 0.3, 6.2,
and 4.8% of wild-type ADA activity, respectively (41). Ex-
periments with these mutants were performed with less
ADA activity than under standard conditions. However,
75% to .90% of the added ADA activity coeluted with
DPPIV activity (Fig. 2 C), suggesting that these mutations
did not impair CD26 binding. Association of 35S-labeled
R142Q in vitro translation product with CD26 was unde-
tectable by PAGE, whereas 35S-labeled E217K, an active
site mutant with ,0.005% of wild-type ADA activity (41,
44), showed normal binding (Fig. 2 D). Reduced CD26
binding by the R142Q mutant was of particular interest
because (a) glutamine is the “wild-type” amino acid at po-
sition 142 in mouse ADA, and (b) R142Q was identified in
a healthy adult whose other ADA allele was not expressed
(38).
In the crystal structure of murine ADA, Gln142 lies in
the 18-residue segment 126–143, which forms the periph-
eral a2 helix (44; Fig. 3). A hybrid consisting of human
ADA substituted with mouse residues 126–143 (referred
to as “m126–143”) expressed 36% of wild-type human
ADA activity in SØ3834 (Table III), but it showed mini-
mal binding to CD26 by FPLC (Fig. 2, A and B) and none
by PAGE (not shown). Binding was also reduced mark-
edly in other hybrids that possessed the murine a2 helix
Figure 1. Binding of recombinant wild-type human and mouse ADA
to rabbit CD26. (A and B) FPLC assay. Lysates of E. coli SØ3834 cells
containing equal units of wild-type human ADA (A) or wild-type mouse
ADA (B) were incubated in the absence (open circles) or presence (filled
circles) of rabbit CD26, then fractionated on Superose 12. Circles, ADA
activity; triangles, DPPIV activity. (C) Nondenaturing PAGE assay. 35S-
labeled ADA in vitro translation products were incubated in the presence
(1) or absence (2) of rabbit CD26 and then subjected to nondenaturing
PAGE, followed by fluorography. Lane 1, wild-type human ADA; lane 2,
wild-type human ADA plus rabbit CD26; lane 3, wild-type mouse ADA;
lane 4, wild-type mouse ADA plus rabbit CD26.1228 Binding Site of Adenosine Deaminase for CD26/Dipeptidyl Peptidase IV
residues (Fig. 2, A and B). Hybrids in which all other re-
gions of human ADA, except for residues 126–143, were
replaced with their murine counterparts had substantial
ADA activity (Table III) and showed essentially normal
CD26 binding (Fig. 2, A and B). Modifying mouse ADA
by substituting human residues 126–143 for the corre-
sponding mouse residues (“h126–143”), or by making the
Q142R point mutation, conferred some ability to bind
CD26, which could be appreciated by FPLC (Fig. 2, A–C).
Together, these results show that the amino acids crit-
ical for CD26 binding lie within segment 126–143 of hu-
man ADA.
As bovine ADA also binds CD26, we amplified cDNA
carrying the ADA coding region from bovine thymus
RNA. The predicted amino acid sequences of residues
115–150 of human, bovine, and murine ADA are com-
pared in Fig. 3. Within segment 126–143, human and bo-
vine ADA differ at only 2 of 18 positions, whereas human
and murine ADA differ at 5, and murine and bovine ADA
at 4 positions. The most notable differences are (a) residues
141–143 of human and bovine ADA are all charged, Glu-
Arg-Asp, whereas only Glu141 is charged in the mouse se-
quence, Glu-Gln-Ala; and (b) residue 131 in mouse ADA
is Asp, whereas Ala and Ser are found in human and bovine
ADA, respectively. We prepared mutants of human ADA
in which a2 helix residues from murine ADA replaced the
corresponding human residues. All were active when ex-
pressed in E. coli SØ3834 (data not shown), but they fell
into two groups with respect to CD26 binding. The single
mutants E128D, A131D, G134N, and D143A all showed
CD26 binding in the FPLC assay (Fig. 2 C). Binding by
the double mutants E128D/R142Q and R142Q/D143A,
the triple mutant E128D/R142Q/D143A, and the qua-
druple mutant E128D/A131D/R142Q/D143A was in
each case reduced, but comparable to that of R142Q alone
(Fig. 2 C).
Binding of Recombinant ADAs to Human T Cell–associated
CD26. The AlNe HTLV-1 transformed T cell line is de-
rived from an immunodeficient patient homozygous for a
mutation in ADA intron 10 that activates a cryptic 39 splice
site (45). ADA activity was unmeasurable in extracts of
AlNe cells when cultured in serum-free (ADA-free) me-
dium, and ADA protein could not be detected by im-
munoblotting with polyclonal Ab to human ADA (not
Figure 2. Binding of rabbit CD26 by human–
mouse ADA hybrids and ADA point mutants. (A
and B) FPLC assay of human–mouse ADA hybrids.
Hybrid structures are shown as bars in which white
indicates human (h) and black indicates mouse (m)
ADA amino acid residues (numbered beside bars).
Gray bars in A and B show the percentage of input
ADA activity associated with DPPIV activity (A),
or the units of ADA bound per unit of DPPIV (B).
Error bars (SD) shown for wild-type human ADA
(A–C) and the R142Q mutant (C) are based on
five and four standard binding experiments (see
Materials and Methods), respectively. (C) FPLC as-
say of human (Hum) and mouse (Mus) ADA point
mutants. Black bars are mutants found in ADA-
deficient individuals; gray bars are mutants prepared
for this study from human or mouse wild-type
cDNA, as indicated. Standard FPLC assay conditions were used for screening the hybrids and point mutants, except for the R149Q, A215T, P126Q mu-
tants from ADA-deficient individuals. In those cases, a lower amount of ADA activity was used, accounting for a greater percentage of input ADA activ-
ity becoming associated with CD26/DPPIV than was found with wild-type human ADA. (D) Nondenaturing PAGE assay. Lane 1, wild-type (WT) hu-
man ADA; lane 2, wild-type human ADA plus rabbit CD26; lane 3, R142Q human ADA mutant; lane 4, R142Q plus rabbit CD26; lane 5, E217K
human ADA mutant; lane 6, E217K plus rabbit CD26.1229 Richard et al.
shown). AlNe cells express a substantial level of CD26 (see
below). We compared the binding of several recombinant
ADAs to CD26 on AlNe cells (see Figs. 4–6).
Virtually no ADA activity was found in Superose 12–
fractionated extracts of AlNe cells that had been incubated
with a high concentration (400 nmol/min) of recombinant
murine ADA (Fig. 4 A), or with the m126–143 human–
mouse hybrid (Fig. 4 B). After incubation with wild-type
human ADA, 91% of cell-associated ADA activity coeluted
with DPPIV, resulting in a ratio of ADA to DPPIV activity
in this peak of 3.7 (Fig. 4 A). With the R142Q mutant,
z40% as much total ADA activity became cell associated as
was found with wild-type human ADA. However, only
9% of the bound R142Q ADA activity coeluted with DP-
PIV, resulting in a ratio of R142Q ADA to DPPIV activity
of 0.1 (Fig. 4 B). Virtually identical results were obtained
for wild-type human ADA and the R142Q mutant in a
second experiment using the same protocol. The R142Q
ADA activity eluting as a 41-kD monomer may have re-
sulted from unstable binding of mutant ADA to CD26 on
AlNe cells, with subsequent dissociation in the extract or
during FPLC. This transient binding probably reflects the
high concentration of exogenous ADA activity used in
these experiments (see below).
We next examined binding of recombinant ADAs to the
surface of AlNe cells by flow cytometry, using mouse mAb
1C5 to human ADA. Western blot experiments indicated
that 1C5 recognizes a COOH-terminal epitope present in
human but not in mouse ADA, and it reacts approximately
as well with the R142Q and E217K mutants as with wild-
type human ADA (Fig. 5). In these experiments (and in
flow cytometry studies shown below in Fig. 6 D), equal
units of R142Q and wild-type ADA activity were com-
pared (Fig. 5 A), whereas equal amounts of total SØ3834
lysate protein were used to compare E217K and wild-type
ADA (Fig. 5 B). Taken together with previous studies of
expression (38, 41), these results indicate that the R142Q
protein has the same activity per molecule as wild-type
ADA, but is somewhat less stable in cells, whereas the
E217K protein is about as stable as the wild-type enzyme,
but is catalytically inactive. The stability of E217K is un-
usual because most ADA missense mutations identified in
SCID patients result in unstable proteins that are difficult to
detect with antisera to ADA, both in patient-derived cell
lines and when expressed in E. coli SØ3834 (41, 46).
In flow cytometry experiments, AlNe cells expressed
high levels of CD26 (Fig. 6 A). They did not bind anti-
ADA mAb 1C5 (Fig. 6 B). Incubating AlNe cells with re-
combinant wild-type human ADA (followed by washing)
induced 1C5 binding (Fig. 6, C and D), as did the R142Q
and E217K mutants (Fig. 6 D). 1C5 binding increased with
the amount of ADA to which the cells were exposed (Fig.
6 D). Based on mean fluorescence values, at the lowest
concentrations tested, E217K induced about half the 1C5
binding induced by wild-type ADA, but equivalent bind-
ing occurred at the higher end of the range (because ex-
pression in SØ3834 is somewhat variable [41], the amounts
of wild-type and E217K ADA protein may not have been
identical). 1C5 binding was detected at all concentrations
of wild-type and E217K proteins tested, but was not mea-
surable with R142Q ADA at 0.3 and 1.7 nmol/min per ml
medium. Wild-type ADA induced 7.5-fold more 1C5
binding than R142Q at ADA activities of 8.3 and 42
nmol/min, and fourfold greater binding at 209 nmol/min
(very similar results were found in a second experiment not
shown). ADA bound to CD26 is derived from an extracel-
lular source (47). Serum ADA1 activity (the isozyme de-
rived from the ADA gene) for 320 normal humans was re-
ported to be 4.2 6 1.5 nmol/min per ml (48). Thus, under
physiological conditions, binding of circulating R142Q
ADA to T cells via CD26 may be 10-fold lower than
normal.
Binding of Naturally Occurring R142Q ADA to Human
CD26. Human ADA expressed in E. coli might interact
differently with CD26 than would ADA produced in hu-
man cells. To address this possibility, we studied the bind-
ing of ADA in extracts of erythrocytes and cultured T cells
from the individual in whom the R142Q allele was identi-
fied, whose second ADA allele carries a nonsense mutation
in codon 3 (38). A limited quantity of R142Q cells was
Figure 3. Location of the a2 helix (CD26 binding site) in the murine
ADA crystal structure. The RasMol model is based on coordinates, as re-
ported (reference 44). The a2 helix (residues 126–143) is shown in or-
ange, with space-filling display of residues D131, Q142, and A143. For
orientation, the COOH-terminal helix (residues 337–351) is shown in
blue. Bound inhibitor (rose) and the zinc ion (yellow) are space-filling
structures at the active site. The panel below the model compares the par-
tial amino acid sequences (residues 115–150) of human (HUM), murine
(MUS), and bovine (BOV) ADA. Amino acids 126–143 of human ADA,
green letters; amino acids D131, Q142, and A143 of murine ADA, red
letters; other amino acids of bovine and murine ADA that differ from the
human sequence, blue letters.1230 Binding Site of Adenosine Deaminase for CD26/Dipeptidyl Peptidase IV
available for these studies, but the results support those ob-
tained with the recombinant enzyme.
As a control for the erythrocyte studies, we used red cells
from an ADA heterozygote whose nonwild-type allele also
has a nonsense mutation. ADA activities of the control and
R142Q hemolysates was 18.8 and 5.5 nmol/h per mg pro-
tein (normal: 63 6 41 nmol/h per mg), respectively. As
erythrocytes lack CD26, we examined CD26 binding by
incubating aliquots of hemolyzed red cells with AlNe T
cells (ADA-deficient). After washing, Triton X-100 ex-
tracts of the AlNe cells were analyzed by FPLC (Fig. 7 A).
About 2.6-fold more control (wild-type) than R142Q
ADA activity eluted as monomer, proportional to the
amounts of ADA activity in the incubations. However,
z14-fold more control (wild-type) than R142Q ADA ac-
tivity coeluted with DPPIV activity.
For the T cell studies we assessed the interaction of en-
dogenous ADA with endogenous CD26 (Fig. 7 B). The
control T cells were obtained from an individual presumed
to be homozygous for wild-type ADA. ADA activity of the
control and R142Q T cell extracts were 1,750 and 592
nmol/h per mg protein, respectively; they expressed ap-
proximately equal levels of CD26 by flow cytometry (not
shown). After FPLC fractionation of lysates of these cells,
z1.6-fold more control (wild-type) than R142Q ADA ac-
tivity eluted as monomer, whereas 45-fold more control
than R142Q ADA activity coeluted with DPPIV activity,
resulting in ratios of ADA units bound per unit CD26 of 1.8
for the control and 0.03 for the R142Q T cells (Fig. 7 B).
Discussion
Murine ADA has a parallel a/b architecture with an
eight-stranded central b barrel and eight peripheral a he-
lixes; the active site containing an essential Zn21 ion lies at
the COOH-terminal end of the b barrel (44; Fig. 3). Hu-
man ADA is 83% identical in sequence and presumably has
the same overall structure. Using a panel of recombinant
human–mouse hybrids that retain catalytic activity, we
have identified the COOH end of the peripheral a2 helix
as the primary determinant of the difference in the ability
of mouse and human ADA to bind CD26/DPPIV. Re-
placing the entire 18-residue segment in human ADA with
murine residues 126–143 modestly reduced the expression
of ADA activity in E. coli, but abolished stable binding to
rabbit and human CD26. Both effects could largely be
achieved by replacing Arg142 of human ADA with Gln,
the residue found at this position in murine ADA. At the
resolution of our screening assays, human to mouse substi-
tutions at the other four nonidentical positions within this
segment did not reduce CD26 binding significantly, and in
various combinations with R142Q they had no greater ef-
fect than the R142Q substitution alone. Making the con-
verse Q142R substitution in mouse ADA, or introducing
the entire human 126–143 segment, conferred some ability
to bind rabbit CD26. No other regions of human ADA
appear to be involved in CD26 binding, including the
Figure 4. Association of recombinant ADAs with CD26/DPPIV on
the AlNe human ADA-deficient T cell line. (A) Binding of wild-type hu-
man ADA (hum; filled circles) and wild-type mouse ADA (mus; open
circles). (B) Binding of the m126–143 human–mouse ADA hybrid (filled
circles) and the R142Q human ADA mutant (open circles). Circles, ADA
activity; triangles, DPPIV activity.
Figure 5. Western blot of re-
combinant ADAs with mAb
1C5 (A–C) or polyclonal antise-
rum (D). (A) Lanes 1 and 3,
wild-type human ADA; lanes 2
and 4, the R142Q mutant. Equal
amounts of wild-type and
R142Q ADA activity were
loaded: 209 nmol/min in lanes 1
and 2, and 42 nmol/min in lanes
3 and 4. (B) Lanes 1 and 3, wild-
type human ADA; lanes 2 and 4,
the E217K mutant. Equal
amounts of wild-type and
E217K extract protein were
loaded: 15 mg in lanes 1 and 2; 3
mg in lanes 3 and 4 (for wild-
type ADA, this represented 209 and 42 nmol/min in lanes 1 and 3, re-
spectively). (C) All lanes were loaded with 12.5 nmol/min of ADA activ-
ity. Lane 1, wild-type human ADA; lane 2, wild-type mouse ADA; lane
3, hybrid h1–337/m338–352 (amino acids 1–337 from human and 338–
352 from mouse ADA sequences; for comparison with results shown in
Table III, this hybrid expressed 2.8 mmol/min of ADA activity, or 85% of
wild-type human ADA); lane 4, hybrid m1–247/h248–363 (see Table
III). (D) As described for C, except that the blot was probed with a goat
anti-ADA antiserum as described previously (41). WT, wild-type; Mut,
mutant; H, human, M, mouse.1231 Richard et al.
11 COOH-terminal residues, which are absent in mu-
rine ADA.
Residues 294 (Leu) and 340–343 (Leu-Val-Ala-Arg) of
human CD26 have been identified as essential for binding
ADA (22, 23). It was postulated that stable ADA–CD26
binding is due to contacts between these CD26 residues
and a nonconserved hydrophobic surface of human ADA,
possibly involving residues Leu346, Ala350, and Gly352,
which are respectively Arg, Glu, and Gln in mouse ADA
(23). This cannot be correct because the human–mouse
ADA hybrid h1–247/m248–352 binds CD26 (Fig. 2).
Moreover, residues 141–143 are Glu-Arg-Asp in human
and bovine ADA, each of which binds CD26, and Glu-
Gln-Ala in mouse ADA, which does not, suggesting that
charged residues of ADA are critical for binding CD26.
This type of contact between proteins, involving mainly
hydrophobic residues of one partner and charged residues
of the other, is not unique, and has recently been observed
in the complex of hen egg white lysozyme with the an-
tilysozyme mAb HyHEL-63 (49). Stable ADA–CD26
binding may also arise from interactions of the critical hy-
drophobic CD26 and charged ADA residues, not with each
other, but with other partners that will be identified when
the 3D structures of human ADA and a CD26–ADA com-
plex have been determined.
Significance of the R142Q Mutation. Most patients with
ADA deficiency have SCID, but 15–20% have a milder
immune deficit with a later clinical onset (37, 45, 50).
Screening of populations and studies of the relatives of pa-
tients with SCID has identified some healthy individuals,
most of African ancestry, with low or absent ADA activity
in red cells, but 5–70% of normal activity in nucleated cells;
this “partial ADA deficiency” has been shown to result
from several different missense mutations (37, 39, 51). Red
cells of subjects with partial ADA deficiency show no (or
minimal) accumulation of dAdo nucleotides (dAXP),
whereas a massive increase occurs in patients with SCID,
and a more modest elevation in those with milder immune
deficiency (3, 41, 45, 52). This correlation, and evidence
that dATP is toxic to lymphoid cells and can induce apop-
tosis by p53- and caspase-dependent mechanism(s) (53–59),
has implicated dAdo-induced dATP pool expansion as the
principal cause of lymphopenia in ADA deficiency.
With this background, the finding of ,20% of normal
red cell ADA activity in the healthy Somalian father of a
child with SCID led to our discovery that he had transmit-
ted an ADA allele with a codon 3 nonsense mutation to his
affected daughter, and that his second ADA allele carried
the R142Q mutation (38). We postulated that the R142Q
mutation, which is distant from the active site, reduced cel-
lular ADA activity by impairing enzyme folding or stability,
but that residual activity due to the R142Q allele was suffi-
cient to catabolize dAdo, preventing dATP accumulation
and immune deficiency. Our present studies with the 1C5
anti-ADA mAb show that the R142Q protein has a spe-
cific activity per molecule close to that of wild-type human
ADA. In our original report of the R142Q allele, we also
identified SCID patients who were homozygous for a
codon 142 nonsense mutation (38). Both the R142Q and
R142X mutations arose from a CGA (Arg) codon. We
Figure 6. Flow cytometry analysis of CD26 and ADA
on the surface of AlNe cells. (A) CD26 expression. Shown
are reactivity of AlNe cells with PE-conjugated anti-CD26
mAb Ta1 (shaded histogram) and control mAb IgG1-PE
(open histogram). (B and C) ADA. Anti-ADA mAb 1C5
binding to AlNe cells that had been washed after incuba-
tion with lysate of untransformed SØ3834 (B) or with ly-
sate of SØ3834 expressing wild-type human ADA (400
nmol/min per ml of medium) (C). (D) Binding of wild-
type (wt) human ADA (circles), R142Q (triangles), and
E217K (squares) ADA mutants. AlNe cells were incubated
with 0.3, 1.7, 8.3, 42, 209, and 400 nmol/min per ml of
recombinant wild-type and R142Q ADAs. The amounts
of E217K-expressing SØ3834 lysate protein used (0.024–
30 mg) were made equal to wild-type ADA lysate protein.
After washing, cell surface–associated ADA was deter-
mined by reactivity of mAb 1C5 and flow cytometry. For
clarity, the horizontal axis shows only units of ADA activ-
ity. Data shown are from one of two experiments.1232 Binding Site of Adenosine Deaminase for CD26/Dipeptidyl Peptidase IV
speculated that during murine evolution there might have
been some advantage in replacing this Arg codon, which
contains a mutagenic CpG dinucleotide, with a CAA Gln
codon (38). Our finding that Arg 142 is the “keystone” of
the bridge between ADA and CD26 permits an additional
speculation: that at the protein level, a Gln142 residue
might have conferred some evolutionary advantage on
mice by reducing interaction between ADA and CD26.
Our studies of CD26 binding by the R142Q and E217K
mutants, derived from ADA-deficient individuals with dis-
tinctive phenotypes, are relevant to theories implicating
CD26 in the pathogenesis of the immune defect in ADA
deficiency. These have postulated either: (a) that ADA
binding per se (unrelated to catalytic activity) is crucial to
an essential function of CD26 in lymphocyte development
or activation (27, 60); or (b) that CD26-bound “ecto-
ADA”, by controlling the level of extracellular Ado, regu-
lates signaling through cell surface Ado receptors (assumed
to be critical for lymphocyte development or function [15,
24, 27, 47]). The first hypothesis ignores evidence, dis-
cussed above, of the correlation between mutant ADA cat-
alytic activity and the metabolic and clinical phenotypes of
ADA-deficient individuals (3, 41, 61). The ADA active site
mutation E217K was identified in a patient with early onset
SCID, whose other ADA allele is not expressed (40). We
have shown that the catalytically inactive E217K protein is
stable and binds to CD26 on the surface of T cells in a
manner similar to wild-type human ADA, suggesting that
ADA–CD26 binding is not sufficient to preserve immune
function.
The second hypothesis, that CD26-bound “ecto-ADA”
regulates levels of extracellular Ado, has been supported by
in vitro studies showing lesser effects of exogenous Ado
(0.1–10 mM) on proliferation and IL-2 production by
CD26-transfected compared with untransfected Jurkat cells
(47). Flow cytometry with anti-ADA antiserum indicated
that only the former possessed cell surface–associated ADA
(although CD26 on these cells was not saturated with
ADA). Whole cell lysates of the transfected and untrans-
fected cells had the same total ADA, as estimated by West-
ern blotting. The physiologic relevance and interpretation
of these observations may be questioned. The Ado concen-
trations used were at least 100-fold higher than occurs in
normal plasma and at least 10-fold higher than has been
found in plasma of patients with ADA deficiency (3). The
differences in proliferation and IL-2 production observed
were attributed to different rates of Ado deamination (de-
spite identical total ADA levels), but this was not measured.
This result, if true, would be surprising because ADA sub-
strates (at physiologic levels) can equilibrate efficiently
across the cell membrane via a ubiquitous, nonconcentra-
tive nucleoside transporter (62). As a result of this transport,
transfused ADA1 erythrocytes (63) and polyethylene gly-
col–modified ADA acting in plasma (64) can correct meta-
bolic abnormalities in cells of ADA-deficient individuals.
Ado receptor–mediated signaling is functional in mice
despite the lack of ADA–CD26 binding. In addition, a
strain of Fischer 344 rats is homozygous for a CD26/DP-
PIV missense mutation that abolishes both peptidase cata-
lytic activity and cell surface expression of the protein (65,
66). Studies of these rats have indicated a role for DPPIV in
renal and intestinal hydrolysis and absorption of prolyl
dipeptides (67, 68). Neither CD26/DPPIV-deficient rats
nor normal mice manifest the purine metabolic abnormali-
ties and profound immunodeficiency (or nonlymphoid pa-
thology) associated with ADA deficiency in humans and
mice.
Advocates of ADA–CD26 hypotheses may consider ro-
dents to be poor models for ADA deficiency in humans
(24). In this regard our observations have special relevance.
There is good evidence that ADA bound to CD26 on hu-
man T cells is not derived from within these cells, but is ac-
quired from the extracellular space (possibly after release
from senescent cells [47]). In the range of ADA activity
found in normal human plasma (48), we observed z10-
Figure 7. Binding of naturally occurring R142Q ADA to human
CD26. (A) Binding of ADA from erythrocyte lysates (RBC) to CD26
from AlNe T cells. 107 AlNe T cells in 1 ml medium were incubated 2 h
at 378C with 0.2 ml aliquots of control (filled circles) and R142Q (open
circles) hemolysates. ADA activities present in the control and R142Q
binding assays were 10.9 and 4.7 nmol/min, respectively. The AlNe cells
were then washed, lysed, fractionated on Superose 12, and assayed as de-
scribed in Materials and Methods. Circles, ADA activity; triangles, DP-
PIV activity. (B) Binding of endogenous T cell ADA to endogenous T
cell CD26. 2 3 107 control (filled circles) and R142Q (open circles) T
cells were lysed, fractionated on Superose 12, and assayed as in A, except
that the Superose 12 column was equilibrated and eluted with 50 mM
Tris-HCl, pH 8.4, 150 mM NaCl (see Materials and Methods). Circles,
ADA activity; triangles, DPPIV activity.1233 Richard et al.
fold less binding of recombinant R142Q than wild-type
human ADA to CD261 ADA2 AlNe T cells. The defect in
CD26 binding was even greater with ADA from erythro-
cytes and T cells obtained from the R142Q-expressing
subject (Fig. 7). It is reasonable to expect that his lympho-
cytes and other tissues also have a markedly reduced level
of ADA-ligated CD26 in vivo. The existence of a healthy
adult with defective ADA–CD26 binding suggests that in-
teraction of these proteins is not essential for the develop-
ment or maintenance of immune function in humans, as is
certainly the case in mice and perhaps some other species.
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